Envoy Medical CEO granted 200,000 stock options

Envoy Medical, Inc. Chief Executive Officer Brent T. Lucas reported a new stock option grant.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Envoy Medical, Inc. Chief Executive Officer Brent T. Lucas reported a new stock option grant. On 02/05/2026, he received 200,000 stock options to buy Class A Common Stock at an exercise price of $0.53 per share, granted at no cost.

According to the vesting schedule, options to purchase 50,000 shares vest on 02/05/2027, and 150,000 additional shares vest pro rata on the 5th of each month thereafter for 36 consecutive months. Following this grant, he holds 234,590 Class A Common shares, 879,749 previously granted stock options, and 110,987 warrants, all held directly.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 4 txns

Insider Lucas Brent T.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	200,000	$0.00	$0.00
holding	Stock Option (right to buy)	--	--	--
holding	Warrant (right to buy)	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 1,079,749 contracts for 879,749 underlying shares (Direct); Warrant (right to buy) — 110,987 contracts (Direct); Class A Common Stock — 234,590 shares (Direct)

Footnotes (3)

F1. Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
F2. Fully exercisable.
F3. Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Envoy Medical (COCH) report for Brent Lucas?

Envoy Medical reported that Chief Executive Officer Brent T. Lucas received a grant of 200,000 stock options on 02/05/2026. These options allow him to purchase Class A Common Stock at a set exercise price, expanding his equity-based compensation and potential future ownership.

How many Envoy Medical stock options were granted to the CEO and at what price?

Brent T. Lucas was granted 200,000 stock options to buy Envoy Medical Class A Common Stock at an exercise price of $0.53 per share. The grant itself was reported at a price of $0 for the derivative security on the transaction date.

What are the vesting terms for Brent Lucas’s new Envoy Medical option grant?

The filing states that options to purchase 50,000 shares vest on 02/05/2027. The remaining 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months, creating a multi-year vesting schedule tied to continued service.

What Envoy Medical equity holdings does Brent Lucas report after this transaction?

After the reported transaction, Brent T. Lucas holds 234,590 shares of Envoy Medical Class A Common Stock directly. He also holds 879,749 stock options with a $2.40 exercise price and 110,987 warrants with an $11.50 exercise price, alongside the new 200,000-option grant.

Does the Form 4 for Envoy Medical show any stock sales by Brent Lucas?

The Form 4 describes a stock option grant coded as an acquisition of derivative securities, not a sale of common shares. It lists his post-transaction common stock, option, and warrant holdings, but does not report any disposition of Class A Common Stock in this filing.

What roles does Brent T. Lucas hold at Envoy Medical (COCH)?

The filing identifies Brent T. Lucas as both a Director and the Chief Executive Officer of Envoy Medical, Inc. He is not marked as a 10% owner. The reported equity awards and holdings therefore reflect compensation and ownership tied to his leadership and board roles.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/09/2026 - 05:45 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lucas Brent T.

(Last)

(First)

(Middle)

C/O 4875 WHITE BEAR PARKWAY

(Street)

WHITE BEAR LAKE

55110

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Envoy Medical, Inc. [ COCH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock								234,590	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.4							⁽¹⁾	10/15/2033	Class A Common Stock	879,749		879,749	D
Warrant (right to buy)	$11.5							⁽²⁾	09/29/2028	Class A Common Stock	110,987		110,987	D
Stock Option (right to buy)	$0.53	02/05/2026		A		200,000		⁽³⁾	02/05/2036	Class A Common Stock	200,000	$0	200,000	D

Explanation of Responses:

1. Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

2. Fully exercisable.

3. Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

	s/ Andrew Nick as Attorney-in-Fact for Brent Lucas pursuant to Power of Attorney previously filed.	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR